Biosimilars And Biologics market
Biosimilars And Biologics Market by Product Class, Application & Region | Forecast 2022 to 2032.
Biosimilars and Biologics Market Players are Redefining the Standards of Efficiency. Get to Know More with FMI
Biosimilars and Biologics Market Outlook (2022 to 2032)
The biosimilars and biologics market is expected to grow at a CAGR of 15.5% during the period 2022 to 2032. The market is valued at US$ 22,490.62 Million in 2022 and is expected to reach a valuation of US$ 95,021.37 Million by 2032.
Some of the factors which are expected to surge the market growth during the forecast period are:
- The increasing price of drugs, coupled with an increase in the costs associated with the healthcare sector.
- The introduction of innovative technologies is expected to create better versions of the existing biosimilars and biologics products.
Biosimilars require very less research as compared to reference biologics, because of which a lot of time is saved.
|
Report Attribute |
Details |
|
Biosimilars and Biologics Market Value (2022) |
US$ 22,490.62 Million |
|
Biosimilars and Biologics Market Anticipated Value (2032) |
US$ 95,021.37 Million |
|
Biosimilars and Biologics Market Projected Growth Rate (2022 to 2032) |
15.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Europe is currently the Largest Biosimilars and Biologics Market
Europe is presently the largest market for biosimilars and biologics and has a market share of a whopping 41%. The region is expected to retain the title during the forecast period as well.
Europe is a region that is meant for presenting large patents in the field of biologics and biosimilars. This indicates the fact that once the products are made available in the market, Europe becomes the first region where such products are launched.
The region is also meant for a large number of people suffering from chronic disorders. This as well makes Europe a hot market. Apart from that, Europe is also home to most of the key market players in this niche.
North America to Remain a Significant Biosimilars and Biologics Market
North America is the second-largest market for biosimilars and biologics. The region has a market share of 28% and is expected to remain the second-largest market during the forecast period as well.
The region has been observing a lot of technological advancements in the field of biopharma.
Apart from that, even the FDA is investing huge amounts in the development of biologics and biopharma. Recently, FDA awarded US$ 1.3 Million to the biologics and biosimilars consortium. The funding has been done to invest in Research and Development for increasing the efficiency of biosimilars and biologics.
Certain provisions were signed in the Inflation Reduction Act. Based on the act, an 8% add-on fee that Medicare Part B will pay healthcare providers for qualifying biosimilars. The increase from the previous 6% to 8% would be having a positive impact on the biosimilars and biologics market. This move is expected to increase competition in the market, promote access to quality healthcare, and will save taxpayers money.
Find your sweet spots for generating winning opportunities in this market.
With eyes set on Serving Lower- and Middle-income Countries the Key Players are on a Mission to Develop Top-quality mRNA-based Influenza Vaccine
The key players in the biosimilars and biologics market are currently testing the efficacy, safety, and tolerability of the mRNA influenza vaccine, and the study is being conducted mainly in the USA. These will work mainly on the genetic sequences of the virus, which will lead to improved strain match and increase the manufacturing capability as well.
The key players are entering into a strategic collaboration with each other to open new centers of Biosimilar across nations. For example, in May 2022, Biocon Biologics Ltd. agreed with Viatris to launch Abvemy in Canada, which is an oncology biosimilar.
Most importantly, the key players are also working on a biosimilar pipeline, while also disclosing the results associated with the respective tests. The good news is that the tests have been displaying positive results.
The adoption of biosimilars and biologics is rising as it is a biological products similar to a drug approved by the USA FDA & European Medicines Agency. Due to their similarity with the biological product, they have no clinically evidenced and meaningful differences from the reference product. In recent years, the demand for biosimilars and biologics drugs has been rising from biological sources such as bacteria and yeast.
The biosimilars and biologics market share is expected to gain prominence over the forthcoming years due to leading biologic drugs expected to lose exclusivity during the forecast period. Increasing populations, costly drugs, and upsurging costs of healthcare are directly propelling market growth.
Competition in the biosimilars and biologics market is expected to be limited in the market as the drugs are expected to be formed using various types of innovative technologies. The manufacturing companies are exploring producing biopharmaceutical drugs to reduce the price of biologics drugs during the forecast period. However, commercial developments are boosting the market share to another height.
What is the Growth Course of the Biosimilars and Biologics Market?
|
Drivers: |
Factors increasing the demand for biosimilar and biologics drugs include rising global disease incidences and better access to healthcare for all nations. Furthermore, the drugs differ due to variability in raw material and manufacturing, which is likely to increase the adoption of biosimilar and follow-up biologics. |
|
Restraints: |
Restraints in the biosimilar and biologics market include constraints in developing and registering biosimilar drugs and the complexity of the manufacturing processes. The drugs are challenging to verify and have to undergo complex regulations. Other restraints in the market include top manufacturers losing patent extensions, cuts in healthcare costs across nations, and forming of incentivized pricing policies by companies. There are also risks in increasing the versions of an identical biosimilar drug. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Regional Analysis
Contribution of the Europe Region to the Biosimilars and Biologics Market
Depending on geographic regions, the biologics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Across the other geography, Europe dominates the biosimilars and biologics market share by acquiring 41% of the share during the forecast period.
European biosimilars and biologics market opportunities are driven by technically advanced healthcare infrastructure and, high patient awareness & regulatory harmonization.
Highlights of the North America Biosimilars and Biologics Market
The North American biosimilars and biologics market size is likely to grow faster in recent years. North America acquires 28% of the share, the second highest after Europe during the forecast period.
However, rising technological advancements in healthcare and the systematic drug review process have increased the sales of biosimilars and biologics during the forecast period. Increasing funding for the development of biosimilar drugs, availability of high-quality research infrastructure, and strategies developed by drug makers in recent years.
Start-up Companies Headway the Biosimilars and Biologics Market
The start-ups in the biosimilars and biologics market are creating new innovative ideas that solve many complications and make it easy to change things with their small starts. They are researching and examining to bring the best to the table. Therefore, new players in the market are using several strategies to develop better treatments for patients in recent years.
- Cutiss, a Zurich-based medical regenerative startup company, develops various skin grafts for the patient to treat burns. Such as small burns, large burns, and deep burns, which help to relieve the lower layer of skin tissues. They are also providing clinical trials to their patients.
- Deep Breath Intelligence, CDR-Life, Mirai Foods, and Omne Possibile are a few more startup companies in the biosimilars and biologics market.
Key Competitors Operating in the Biosimilars and Biologics Market
The market is fragmented by the prominent key players present in the market in recent years. They are playing a vital role in increasing market revenue by adopting new and advanced marketing methods.
Some of the marketing methodologies adopted by key vendors are partnerships, mergers, acquisitions, product launches, collaborations, and others during the forecast period.
Recent Development in the Biosimilars and Biologics Market
- In July 2019, Prestige announced an agreement with a Russian-based company named Pharmapark LLC. The partnerships between the company are important to the Prestige of making the availability of Tuznue all around the globe.
- Nihon Kohden opened a hematology analyzer reagent facility in Dubai in 2019.
- Sysmex introduced the CN-6000 and CN-3000 Automated Blood Coagulation Analyzers in 2018.
- Roche Diagnostics introduced the cobas t 711 coagulation analyzer in 2017.
Key Players in Biosimilar Market
- Pfizer Inc. (AC. Hospira)
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories
- Biocon Limited
- Mylan, Inc.
- Amgen
- Celltrion Inc.
- Roche Diagnostics
- Merck KGaA
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 15.5% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016 to 2021 |
|
Forecast Period |
2022 to 2032 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2022 to 2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments
By Product Class:
- Epoetins
- Filgrastim
- Insulins
- Growth Hormones
- Alfa Interferons
- Monoclonal Antibodies
- Beta Interferons
- Follitropins
- Low-molecular-weight Heparins (LMWH).
By Application:
- Rheumatoid arthritis
- Anemia
- Cancer
- Diabetes
- Others
By Region:
- Asia Pacific
- Europe
- North America
- Latin America
- Middle East and Africa
Frequently Asked Questions
What is the Growth Outlook for the Biosimilars and Biologics Market?
The biosimilars and biologics market is predicted to advance at a CAGR of 15.5% from 2022 to 2032.
Which Region Leads the Biosimilars and Biologics Market?
Europe is anticipated to lead the biosimilars and biologics market during the forecast period.
What is the Growth Potential does Biosimilars and Biologics Market?
The biosimilars and biologics market is likely to hold a valuation of US$ 95,021.37 Million by 2032.
Which Sector drives the Biosimilars and Biologics Market?
The pharmaceutical sector is the key driver in the biosimilars and biologics market.
Table of Content
1. Executive Summary | Biosimilars And Biologics market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product Class, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Class, 2022 to 2032 5.3.1. Epoetins 5.3.2. Filgrastims 5.3.3. Insulins 5.3.4. Growth hormones 5.3.5. Alfa interferons 5.3.6. Monoclonal antibodies 5.3.7. Beta interferons 5.3.8. Follitropins 5.3.9. Low-molecular-weight heparins 5.4. Y-o-Y Growth Trend Analysis By Product Class, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Product Class, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2022 to 2032 6.3.1. Rheumatoid arthritis 6.3.2. Anemia 6.3.3. Cancer 6.3.4. Diabetes 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 8.2.1. By Country 8.2.1.1. United States of America 8.2.1.2. Canada 8.2.2. By Product Class 8.2.3. By Application 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Product Class 8.3.3. By Application 8.4. Key Takeaways 9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Product Class 9.2.3. By Application 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product Class 9.3.3. By Application 9.4. Key Takeaways 10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Product Class 10.2.3. By Application 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product Class 10.3.3. By Application 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Malaysia 11.2.1.5. Singapore 11.2.1.6. Australia 11.2.1.7. Rest of Asia Pacific 11.2.2. By Product Class 11.2.3. By Application 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product Class 11.3.3. By Application 11.4. Key Takeaways 12. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of Middle East and Africa 12.2.2. By Product Class 12.2.3. By Application 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product Class 12.3.3. By Application 12.4. Key Takeaways 13. Key Country's market analysis 13.1. United Kingdom 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2021 13.1.2.1. By Product Class 13.1.2.2. By Application 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2021 13.2.2.1. By Product Class 13.2.2.2. By Application 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2021 13.3.2.1. By Product Class 13.3.2.2. By Application 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2021 13.4.2.1. By Product Class 13.4.2.2. By Application 13.5. Rest of Latin America 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2021 13.5.2.1. By Product Class 13.5.2.2. By Application 13.6. Germany 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2021 13.6.2.1. By Product Class 13.6.2.2. By Application 13.7. United Kingdom 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2021 13.7.2.1. By Product Class 13.7.2.2. By Application 13.8. France 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2021 13.8.2.1. By Product Class 13.8.2.2. By Application 13.9. Spain 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2021 13.9.2.1. By Product Class 13.9.2.2. By Application 13.10. Italy 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2021 13.10.2.1. By Product Class 13.10.2.2. By Application 13.11. Rest of Europe 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2021 13.11.2.1. By Product Class 13.11.2.2. By Application 13.12. China 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2021 13.12.2.1. By Product Class 13.12.2.2. By Application 13.13. Japan 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2021 13.13.2.1. By Product Class 13.13.2.2. By Application 13.14. South Korea 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2021 13.14.2.1. By Product Class 13.14.2.2. By Application 13.15. Malaysia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2021 13.15.2.1. By Product Class 13.15.2.2. By Application 13.16. Singapore 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2021 13.16.2.1. By Product Class 13.16.2.2. By Application 13.17. Australia 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2021 13.17.2.1. By Product Class 13.17.2.2. By Application 13.18. Rest of Asia Pacific 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2021 13.18.2.1. By Product Class 13.18.2.2. By Application 13.19. GCC Countries 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2021 13.19.2.1. By Product Class 13.19.2.2. By Application 13.20. South Africa 13.20.1. Pricing Analysis 13.20.2. Market Share Analysis, 2021 13.20.2.1. By Product Class 13.20.2.2. By Application 13.21. Israel 13.21.1. Pricing Analysis 13.21.2. Market Share Analysis, 2021 13.21.2.1. By Product Class 13.21.2.2. By Application 13.22. Rest of the Middle East and Africa 13.22.1. Pricing Analysis 13.22.2. Market Share Analysis, 2021 13.22.2.1. By Product Class 13.22.2.2. By Application 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Product Class 14.3.3. By Application 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Pfizer Inc. 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Sandoz International GmbH 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. Teva Pharmaceutical Industries Ltd. 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Dr. Reddy’s Laboratories 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Biocon Limited 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Mylan, Inc 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Amgen 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. Celltrion Inc 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. Roche Diagnostics 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. Merck KGaA 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032 Table 2: Global Market Value (US$ Million) Forecast by Product Class, 2017 to 2032 Table 3: Global Market Value (US$ Million) Forecast by Application, 2017 to 2032 Table 4: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 5: North America Market Value (US$ Million) Forecast by Product Class, 2017 to 2032 Table 6: North America Market Value (US$ Million) Forecast by Application, 2017 to 2032 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 8: Latin America Market Value (US$ Million) Forecast by Product Class, 2017 to 2032 Table 9: Latin America Market Value (US$ Million) Forecast by Application, 2017 to 2032 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 11: Europe Market Value (US$ Million) Forecast by Product Class, 2017 to 2032 Table 12: Europe Market Value (US$ Million) Forecast by Application, 2017 to 2032 Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 14: Asia Pacific Market Value (US$ Million) Forecast by Product Class, 2017 to 2032 Table 15: Asia Pacific Market Value (US$ Million) Forecast by Application, 2017 to 2032 Table 16: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 17: Middle East and Africa Market Value (US$ Million) Forecast by Product Class, 2017 to 2032 Table 18: Middle East and Africa Market Value (US$ Million) Forecast by Application, 2017 to 2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Product Class, 2022 to 2032 Figure 2: Global Market Value (US$ Million) by Application, 2022 to 2032 Figure 3: Global Market Value (US$ Million) by Region, 2022 to 2032 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032 Figure 7: Global Market Value (US$ Million) Analysis by Product Class, 2017 to 2032 Figure 8: Global Market Value Share (%) and BPS Analysis by Product Class, 2022 to 2032 Figure 9: Global Market Y-o-Y Growth (%) Projections by Product Class, 2022 to 2032 Figure 10: Global Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 11: Global Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 12: Global Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 13: Global Market Attractiveness by Product Class, 2022 to 2032 Figure 14: Global Market Attractiveness by Application, 2022 to 2032 Figure 15: Global Market Attractiveness by Region, 2022 to 2032 Figure 16: North America Market Value (US$ Million) by Product Class, 2022 to 2032 Figure 17: North America Market Value (US$ Million) by Application, 2022 to 2032 Figure 18: North America Market Value (US$ Million) by Country, 2022 to 2032 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 22: North America Market Value (US$ Million) Analysis by Product Class, 2017 to 2032 Figure 23: North America Market Value Share (%) and BPS Analysis by Product Class, 2022 to 2032 Figure 24: North America Market Y-o-Y Growth (%) Projections by Product Class, 2022 to 2032 Figure 25: North America Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 26: North America Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 27: North America Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 28: North America Market Attractiveness by Product Class, 2022 to 2032 Figure 29: North America Market Attractiveness by Application, 2022 to 2032 Figure 30: North America Market Attractiveness by Country, 2022 to 2032 Figure 31: Latin America Market Value (US$ Million) by Product Class, 2022 to 2032 Figure 32: Latin America Market Value (US$ Million) by Application, 2022 to 2032 Figure 33: Latin America Market Value (US$ Million) by Country, 2022 to 2032 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 37: Latin America Market Value (US$ Million) Analysis by Product Class, 2017 to 2032 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Product Class, 2022 to 2032 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Product Class, 2022 to 2032 Figure 40: Latin America Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 41: Latin America Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 43: Latin America Market Attractiveness by Product Class, 2022 to 2032 Figure 44: Latin America Market Attractiveness by Application, 2022 to 2032 Figure 45: Latin America Market Attractiveness by Country, 2022 to 2032 Figure 46: Europe Market Value (US$ Million) by Product Class, 2022 to 2032 Figure 47: Europe Market Value (US$ Million) by Application, 2022 to 2032 Figure 48: Europe Market Value (US$ Million) by Country, 2022 to 2032 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 52: Europe Market Value (US$ Million) Analysis by Product Class, 2017 to 2032 Figure 53: Europe Market Value Share (%) and BPS Analysis by Product Class, 2022 to 2032 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Product Class, 2022 to 2032 Figure 55: Europe Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 56: Europe Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 57: Europe Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 58: Europe Market Attractiveness by Product Class, 2022 to 2032 Figure 59: Europe Market Attractiveness by Application, 2022 to 2032 Figure 60: Europe Market Attractiveness by Country, 2022 to 2032 Figure 61: Asia Pacific Market Value (US$ Million) by Product Class, 2022 to 2032 Figure 62: Asia Pacific Market Value (US$ Million) by Application, 2022 to 2032 Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2022 to 2032 Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Product Class, 2017 to 2032 Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Product Class, 2022 to 2032 Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Product Class, 2022 to 2032 Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 73: Asia Pacific Market Attractiveness by Product Class, 2022 to 2032 Figure 74: Asia Pacific Market Attractiveness by Application, 2022 to 2032 Figure 75: Asia Pacific Market Attractiveness by Country, 2022 to 2032 Figure 76: Middle East and Africa Market Value (US$ Million) by Product Class, 2022 to 2032 Figure 77: Middle East and Africa Market Value (US$ Million) by Application, 2022 to 2032 Figure 78: Middle East and Africa Market Value (US$ Million) by Country, 2022 to 2032 Figure 79: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 80: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 81: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 82: Middle East and Africa Market Value (US$ Million) Analysis by Product Class, 2017 to 2032 Figure 83: Middle East and Africa Market Value Share (%) and BPS Analysis by Product Class, 2022 to 2032 Figure 84: Middle East and Africa Market Y-o-Y Growth (%) Projections by Product Class, 2022 to 2032 Figure 85: Middle East and Africa Market Value (US$ Million) Analysis by Application, 2017 to 2032 Figure 86: Middle East and Africa Market Value Share (%) and BPS Analysis by Application, 2022 to 2032 Figure 87: Middle East and Africa Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032 Figure 88: Middle East and Africa Market Attractiveness by Product Class, 2022 to 2032 Figure 89: Middle East and Africa Market Attractiveness by Application, 2022 to 2032 Figure 90: Middle East and Africa Market Attractiveness by Country, 2022 to 2032
Recommendations
Explore Healthcare Insights
View Reports
